- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Cantor Fitzgerald Lowers Gilead Sciences Price Target
Investment firm reduces price target for biopharmaceutical company's stock
Apr. 10, 2026 at 1:58pm
Got story updates? Submit your updates here. ›
Cantor Fitzgerald's lowered price target on Gilead Sciences stock reflects the volatility and uncertainty facing the biopharmaceutical industry.Foster City TodayInvestment firm Cantor Fitzgerald has lowered its price target for Gilead Sciences (NASDAQ:GILD) from $155.00 to $115.00, while maintaining an 'overweight' rating on the biopharmaceutical company's stock. The new target price represents a potential downside of 18.62% from Gilead's current trading price.
Why it matters
Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Analyst price target adjustments can significantly impact investor sentiment and trading activity around a company's stock.
The details
In a research report released on Friday, Cantor Fitzgerald analysts cited the new $115.00 price target, down from the previous $155.00 target. The firm maintained its 'overweight' rating on Gilead Sciences. Several other research analysts have also recently weighed in on the stock, with some increasing their price targets and others, like Cantor Fitzgerald, lowering theirs.
- Cantor Fitzgerald released the updated price target on April 10, 2026.
The players
Cantor Fitzgerald
An investment firm that provides research coverage and analysis on Gilead Sciences.
Gilead Sciences
A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, with a portfolio anchored by antiviral therapies for HIV and viral hepatitis.
The takeaway
This price target adjustment by Cantor Fitzgerald reflects the ongoing volatility and uncertainty in the biopharmaceutical sector, as analysts weigh factors like pipeline development, competitive dynamics, and market demand when evaluating a company's future growth prospects.
